Leflunomide: is a new oral agent in treatment of acute pancreatitis?
Kutluana U, Oruc N, Nart D, Kaptanoglu B, Yonetci N, Ozutemiz O.
Pancreas · journal article · DOI 10.1097/mpa.0b013e3181bab6a9 PUBLICATION REGISTRY
Go to research.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för leflunomide. Visa hela publikationsregistret
A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publications in the selection
68 hitsMicroarray analysis of Leflunomide-induced limb malformations in CD-1 mice.
Fukushima R, Kaneto M, Kitagawa H.
Reprod Toxicol · journal article · DOI 10.1016/j.reprotox.2009.09.001Investigation of the influence of CYP1A2 and CYP2C19 genetic polymorphism on 2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-butenamide (A77 1726) pharmacokinetics in leflunomide-treated patients with rheumatoid arthritis.
Bohanec Grabar P, Grabnar I, Rozman B, Logar D, Tomsic M, Suput D, Trdan T, Peterlin Masic L, Mrhar A, Dolzan V.
Drug Metab Dispos · research support, non-u.s. gov't; journal article · DOI 10.1124/dmd.109.027482Leflunomide therapy for polyomavirus-induced allograft nephropathy: efficient BK virus elimination without increased risk of rejection.
Teschner S, Gerke P, Geyer M, Wilpert J, Krumme B, Benzing T, Walz G.
Transplant Proc · journal article · DOI 10.1016/j.transproceed.2009.06.099Leflunomide therapy for BK virus allograft nephropathy in pediatric and young adult kidney transplant recipients.
Araya CE, Garin EH, Neiberger RE, Dharnidharka VR.
Pediatr Transplant · journal article; case reports · DOI 10.1111/j.1399-3046.2009.01183.xInhibiting the teratogenicity of the immunosuppressant leflunomide in mice by supplementation of exogenous uridine.
Fukushima R, Kanamori S, Hirashiba M, Hishikawa A, Muranaka R, Kaneto M, Kitagawa H.
Toxicol Sci · journal article · DOI 10.1093/toxsci/kfp022The efficacy and safety of leflunomide therapy in lupus nephritis by repeat kidney biopsy.
Zhang FS, Nie YK, Jin XM, Yu HM, Li YN, Sun Y.
Rheumatol Int · journal article · DOI 10.1007/s00296-009-0861-3Interleukin-13 augments bronchial smooth muscle contractility with an up-regulation of RhoA protein.
Chiba Y, Nakazawa S, Todoroki M, Shinozaki K, Sakai H, Misawa M.
Am J Respir Cell Mol Biol · research support, non-u.s. gov't; journal article · DOI 10.1165/rcmb.2008-0162ocThe changes in serum chemokines following leflunomide therapy in patients with rheumatoid arthritis.
Klimiuk PA, Kita J, Chwiecko J, Sierakowski S.
Clin Rheumatol · clinical trial; journal article · DOI 10.1007/s10067-008-0974-1Genetic polymorphism of CYP1A2 and the toxicity of leflunomide treatment in rheumatoid arthritis patients.
Bohanec Grabar P, Rozman B, Tomsic M, Suput D, Logar D, Dolzan V.
Eur J Clin Pharmacol · research support, non-u.s. gov't; journal article · DOI 10.1007/s00228-008-0498-2Leflunomide-induced subacute cutaneous lupus erythematosus with erythema multiforme-like lesions.
Marzano AV, Ramoni S, Del Papa N, Barbareschi M, Alessi E.
Lupus · journal article; case reports · DOI 10.1177/0961203307087189Leflunomide in subacute cutaneous lupus erythematosus - two sides of a coin.
Suess A, Sticherling M.
Int J Dermatol · journal article; case reports · DOI 10.1111/j.1365-4632.2007.03333.xNew antirheumatic drugs: any real added value? A critical overview of regulatory criteria for their marketing approval.
Bertele' V, Assisi A, Di Muzio V, Renzo D, Garattini S.
Eur J Clin Pharmacol · journal article · DOI 10.1007/s00228-007-0338-9Teratogenicity study of the dihydroorotate-dehydrogenase inhibitor and protein tyrosine kinase inhibitor Leflunomide in mice.
Fukushima R, Kanamori S, Hirashiba M, Hishikawa A, Muranaka RI, Kaneto M, Nakamura K, Kato I.
Reprod Toxicol · journal article · DOI 10.1016/j.reprotox.2007.05.006Mitochondrial protection by the JNK inhibitor leflunomide rescues mice from acetaminophen-induced liver injury.
Latchoumycandane C, Goh CW, Ong MM, Boelsterli UA.
Hepatology · research support, non-u.s. gov't; journal article · DOI 10.1002/hep.21475Leflunomide in psoriatic arthritis.
Kaltwasser JP.
Autoimmun Rev · review; journal article · DOI 10.1016/j.autrev.2006.12.001Leflunomide-induced pneumonitis in a patient with rheumatoid arthritis.
Hirabayashi Y, Shimizu H, Kobayashi N, Kudo K.
Intern Med · journal article; case reports · DOI 10.2169/internalmedicine.45.1455Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis.
Suissa S, Hudson M, Ernst P.
Arthritis Rheum · research support, non-u.s. gov't; journal article · DOI 10.1002/art.21806Treatment of refractory CMV-infection following hematopoietic stem cell transplantation with the combination of foscarnet and leflunomide.
Ehlert K, Groll AH, Kuehn J, Vormoor J.
Klin Padiatr · journal article; case reports · DOI 10.1055/s-2006-933412Anti-Jo-1 antibody positive polymyositis--successful therapy with leflunomide.
Lange U, Piegsa M, Müller-Ladner U, Strunk J.
Autoimmunity · journal article; case reports · DOI 10.1080/08916930600623874[Skin ulceration after leflunomide treatment in two patients with rheumatoid arthritis].
Jakob A, Porstmann R, Rompel R.
J Dtsch Dermatol Ges · journal article; case reports · DOI 10.1111/j.1610-0387.2006.05934.xSevere atopic dermatitis and leflunomide: first clinical experience and highlights of pertinent experimental data.
Wozel G, Vitéz L, Pfeiffer C.
Dermatol Online J · review; journal article; case reports · DOI 10.5070/d36cg6s9t4Disruption of the interaction of T cells with antigen-presenting cells by the active leflunomide metabolite teriflunomide: involvement of impaired integrin activation and immunologic synapse formation.
Zeyda M, Poglitsch M, Geyeregger R, Smolen JS, Zlabinger GJ, Hörl WH, Waldhäusl W, Stulnig TM, Säemann MD.
Arthritis Rheum · research support, non-u.s. gov't; journal article · DOI 10.1002/art.21255[Treatment of proliferative lupus nephritis with leflunomide and steroid: a prospective multi-center controlled clinical trial].
Cui TG, Hou FF, Ni ZH, Chen XM, Zhang FS, Zhu TY, Zhao XZ, Bao CD, Zhao MH, Wang GB, Qian JQ, Cai GY, Li YN, Lu FM, Mei CL, Zou WZ, Wang HY.
Zhonghua Nei Ke Za Zhi · controlled clinical trial; multicenter study; journal articleLeflunomide: new indication. In psoriatic rheumatism: too many risks, too little efficacy.
Författaruppgift saknas
Prescrire Int · comparative study; journal articlePopulation pharmacokinetics of the active metabolite of leflunomide in pediatric subjects with polyarticular course juvenile rheumatoid arthritis.
Shi J, Kovacs SJ, Wang Y, Ludden TM, Bhargava VO.
J Pharmacokinet Pharmacodyn · comparative study; journal article · DOI 10.1007/s10928-005-0049-8Leflunomide: long-term clinical experience and new uses.
Kaltwasser JP, Behrens F.
Expert Opin Pharmacother · review; journal article · DOI 10.1517/14656566.6.5.787The active metabolite of leflunomide, A77 1726, interferes with dendritic cell function.
Kirsch BM, Zeyda M, Stuhlmeier K, Grisar J, Smolen JS, Watschinger B, Stulnig TM, Hörl WH, Zlabinger GJ, Säemann MD.
Arthritis Res Ther · comparative study; research support, non-u.s. gov't; research-article; journal article · DOI 10.1186/ar1727Inhibition of human cytomegalovirus signaling and replication by the immunosuppressant FK778.
Evers DL, Wang X, Huong SM, Andreoni KA, Huang ES.
Antiviral Res · research support, u.s. gov't, p.h.s.; research support, non-u.s. gov't; journal article · DOI 10.1016/j.antiviral.2004.03.007Effects of a short course of leflunomide on T-independent B-lymphocyte xenoreactivity and on susceptibility of xenografts to acute or chronic rejection.
Yan Y, Verbeken E, Yu L, Rutgeerts O, Goebels J, Segers C, Lin Y, Waer M.
Transplantation · research support, non-u.s. gov't; journal article · DOI 10.1097/01.tp.0000147464.63188.4b